Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy

BMJ Case Rep. 2020 Mar 31;13(3):e233263. doi: 10.1136/bcr-2019-233263.
No abstract available

Keywords: cancer intervention; endocrine cancer; pancreatic cancer; radiology; therapeutic indications.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers, Tumor / blood
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy
  • Chromogranin A / blood
  • Humans
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy
  • Lutetium / therapeutic use*
  • Male
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / therapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / therapy
  • Receptors, Peptide / metabolism
  • Remission Induction

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Chromogranin A
  • Organometallic Compounds
  • Receptors, Peptide
  • Lutetium
  • lutetium Lu 177 dotatate
  • Octreotide